DK1515959T3 - Farmaceutiske salte af reboxetin - Google Patents

Farmaceutiske salte af reboxetin

Info

Publication number
DK1515959T3
DK1515959T3 DK03725195T DK03725195T DK1515959T3 DK 1515959 T3 DK1515959 T3 DK 1515959T3 DK 03725195 T DK03725195 T DK 03725195T DK 03725195 T DK03725195 T DK 03725195T DK 1515959 T3 DK1515959 T3 DK 1515959T3
Authority
DK
Denmark
Prior art keywords
reboxetine
pharmaceutical salts
pharmaceutical
salts
Prior art date
Application number
DK03725195T
Other languages
Danish (da)
English (en)
Inventor
Massimo Zampieri
Annalisa Airoldi
Alessandro Martini
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1515959(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of DK1515959T3 publication Critical patent/DK1515959T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03725195T 2002-06-17 2003-06-04 Farmaceutiske salte af reboxetin DK1515959T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077366 2002-06-17
PCT/EP2003/005261 WO2003106441A1 (en) 2002-06-17 2003-06-04 Pharmaceutical salts of reboxetine

Publications (1)

Publication Number Publication Date
DK1515959T3 true DK1515959T3 (da) 2009-11-02

Family

ID=29724495

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03725195T DK1515959T3 (da) 2002-06-17 2003-06-04 Farmaceutiske salte af reboxetin

Country Status (23)

Country Link
US (2) US20070010517A1 (https=)
EP (1) EP1515959B1 (https=)
JP (1) JP4563172B2 (https=)
KR (1) KR100779786B1 (https=)
CN (2) CN1662511B (https=)
AR (1) AR040222A1 (https=)
AT (1) ATE439354T1 (https=)
AU (1) AU2003227755B2 (https=)
BR (1) BR0311878A (https=)
CA (1) CA2489763C (https=)
DE (1) DE60328787D1 (https=)
DK (1) DK1515959T3 (https=)
ES (1) ES2328472T3 (https=)
MX (1) MXPA04011916A (https=)
MY (1) MY131231A (https=)
NO (1) NO329346B1 (https=)
NZ (1) NZ537023A (https=)
PE (1) PE20040565A1 (https=)
PL (1) PL375211A1 (https=)
RU (1) RU2286341C2 (https=)
TW (1) TWI267510B (https=)
WO (1) WO2003106441A1 (https=)
ZA (1) ZA200409624B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20190185438A1 (en) * 2016-12-06 2019-06-20 Tonix Pharmaceuticals Holding Corp. Salts and polymorphs of esreboxetine
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor

Also Published As

Publication number Publication date
ATE439354T1 (de) 2009-08-15
AU2003227755A1 (en) 2003-12-31
US20090291953A1 (en) 2009-11-26
WO2003106441A1 (en) 2003-12-24
JP4563172B2 (ja) 2010-10-13
TW200403230A (en) 2004-03-01
NZ537023A (en) 2006-09-29
KR100779786B1 (ko) 2007-11-28
NO329346B1 (no) 2010-10-04
ES2328472T3 (es) 2009-11-13
AR040222A1 (es) 2005-03-16
RU2286341C2 (ru) 2006-10-27
DE60328787D1 (de) 2009-09-24
NO20050183L (no) 2005-01-12
MXPA04011916A (es) 2005-03-31
PL375211A1 (en) 2005-11-28
EP1515959B1 (en) 2009-08-12
CA2489763A1 (en) 2003-12-24
KR20050019137A (ko) 2005-02-28
RU2005100846A (ru) 2005-06-10
TWI267510B (en) 2006-12-01
CN101298440A (zh) 2008-11-05
PE20040565A1 (es) 2004-09-02
CN1662511A (zh) 2005-08-31
CN1662511B (zh) 2010-06-09
AU2003227755B2 (en) 2009-01-15
CA2489763C (en) 2007-12-18
HK1077572A1 (zh) 2006-02-17
US20070010517A1 (en) 2007-01-11
EP1515959A1 (en) 2005-03-23
ZA200409624B (en) 2006-05-31
JP2005533791A (ja) 2005-11-10
BR0311878A (pt) 2005-04-05
MY131231A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
CY2015036I1 (el) Νεα παραγωγα οξαζολιδινονης
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DE60312780D1 (de) Wegwerfwindel
DK1438306T3 (da) Derivater af UK-2A
DE60336213D1 (de) Chirurgisches klammergerät
DK1381367T3 (da) Oral aripiprazolopløsning
ATE380544T1 (de) Umhüllte feste darreichungsform
FI20020772A0 (fi) Kirurginen implantti
DE60324099D1 (de) Arzneistoffhaltiger tampon
DK1522290T3 (da) Kirurgisk vidvinkelreflektor
DE602004023302D1 (de) Chirurgisches implantat
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1622612T3 (da) Farmaceutisk formulering af natriumsaltet af telmitarsan
DK1410793T3 (da) Administreringsform af ibuprofen-natrium
IS8197A (is) Fjöllaga munnlausnartafla
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
DK1805192T3 (da) Salte af isophosphoramidsennep og analoger deraf som antitumor-midler
DK1578774T3 (da) Oprensning af immunoglobuliner
DE50303099D1 (de) Patientenlagerungstisch
IS8399A (is) Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
DK1515959T3 (da) Farmaceutiske salte af reboxetin
IS7598A (is) Ný sölt
DK1503746T3 (da) Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme